Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics⦠read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
$8.76
Price+2.82%
$0.24
$1.065b
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$130.130m
-
1y CAGR-
3y CAGR-
5y CAGR-$73.910m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.56
-
1y CAGR-
3y CAGR-
5y CAGR$464.574m
$567.302m
Assets$102.728m
Liabilities$17.116m
Debt3.0%
-0.3x
Debt to EBITDA-$174.694m
-
1y CAGR-
3y CAGR-
5y CAGR